Gastrointestinal oncology

Publications 2019

Araghi M, Soerjomataram I, Bardot A, Ferlay J, Cabasag CJ, Morrison DS, De P, Tervonen H, Walsh PM, Bucher O, Engholm G, Jackson C, McClure C, Woods RR, Saint-Jacques N, Morgan E, Ransom D, Thursfield V, Møller B, Leonfellner S, Guren MG, Bray F, Arnold M (2019)
Changes in colorectal cancer incidence in seven high-income countries: a population-based study
Lancet Gastroenterol Hepatol, 4 (7), 511-518
DOI 10.1016/S2468-1253(19)30147-5, PubMed 31105047

Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG (2019)
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy
Ann Oncol (in press)
DOI 10.1093/annonc/mdz139, PubMed 31046124

Lund-Andersen C, Nakken S, Nygård S, Fromm B, Aasheim LB, Davidson B, Julsrud L, Abrahamsen TW, Kristensen AT, Dybdahl B, Larsen SG, Hovig E, Flatmark K (2019)
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response
Cold Spring Harb Mol Case Stud, 5 (2)
DOI 10.1101/mcs.a003566, PubMed 30862609

Olsen JA, Brunborg C, Steinberg M, Persse D, Sterz F, Lozano M, Westfall M, van Grunsven PM, Lerner EB, Wik L (2019)
Survival to hospital discharge with biphasic fixed 360 joules versus 200 escalating to 360 joules defibrillation strategies in out-of-hospital cardiac arrest of presumed cardiac etiology
Resuscitation, 136, 112-118
DOI 10.1016/j.resuscitation.2019.01.020, PubMed 30708074

Rusten E, Rekstad BL, Undseth C, Klotz D, Hernes E, Guren MG, Malinen E (2019)
Anal cancer chemoradiotherapy outcome prediction using 18F-fluorodeoxyglucose positron emission tomography and clinicopathological factors
Br J Radiol, 92 (1097), 20181006
DOI 10.1259/bjr.20181006, PubMed 30810343

Röhrl K, Guren MG, Småstuen MC, Rustøen T (2019)
Symptoms during chemotherapy in colorectal cancer patients
Support Care Cancer (in press)
DOI 10.1007/s00520-018-4598-y, PubMed 30607676

Smeby J, Sveen A, Eilertsen IA, Danielsen SA, Hoff AM, Eide PW, Johannessen B, Hektoen M, Skotheim RI, Guren MG, Nesbakken A, Lothe RA (2019)
Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer
Oncogenesis, 8 (6), 35
DOI 10.1038/s41389-019-0141-3, PubMed 31092812

Publications 2018

Ali AS, Grönberg M, Langer SW, Ladekarl M, Hjortland GO, Vestermark LW, Österlund P, Welin S, Grønbæk H, Knigge U, Sorbye H, Janson ET (2018)
Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
Med Oncol, 35 (4), 47
DOI 10.1007/s12032-018-1103-x, PubMed 29511910

Benitez Majano S, Di Girolamo C, Rachet B, Maringe C, Guren MG, Glimelius B, Iversen LH, Schnell EA, Lundqvist K, Christensen J, Morris M, Coleman MP, Walters S (2018)
Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study
Lancet Oncol, 20 (1), 74-87
DOI 10.1016/S1470-2045(18)30646-6, PubMed 30545752

Bruun J, Sveen A, Barros R, Eide PW, Eilertsen I, Kolberg M, Pellinen T, David L, Svindland A, Kallioniemi O, Guren MG, Nesbakken A, Almeida R, Lothe RA (2018)
Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
Mol Oncol, 12 (9), 1639-1655
DOI 10.1002/1878-0261.12347, PubMed 29900672

Brændengen M, Glimelius B (2018)
Preoperative radiotherapy or chemoradiotherapy in rectal cancer - Is survival improved? An update of the "Nordic" LARC study in non-resectable cancers
Radiother Oncol, 127 (3), 392-395
DOI 10.1016/j.radonc.2018.05.004, PubMed 29778486

Claassen YHM, Dikken JL, Hartgrink HH, de Steur WO, Slingerland M, Verhoeven RHA, van Eycken E, de Schutter H, Johansson J, Rouvelas I, Johnson E, Hjortland GO, Jensen LS, Larsson HJ, Allum WH, Portielje JEA, Bastiaannet E, van de Velde CJH (2018)
North European comparison of treatment strategy and survival in older patients with resectable gastric cancer: A EURECCA upper gastrointestinal group analysis
Eur J Surg Oncol, 44 (12), 1982-1989
DOI 10.1016/j.ejso.2018.09.014, PubMed 30343998

Claassen YHM, Vermeer NCA, Iversen LH, van Eycken E, Guren MG, Mroczkowski P, Martling A, Codina Cazador A, Johansson R, Vandendael T, Wibe A, Moller B, Lippert H, Rutten HJT, Portielje JEA, Liefers GJ, Holman FA, van de Velde CJH, Bastiaannet E (2018)
Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison
Br J Cancer, 119 (4), 517-522
DOI 10.1038/s41416-018-0215-6, PubMed 30057408

Guren MG, Aagnes B, Nygård M, Dahl O, Møller B (2018)
Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016
Clin Colorectal Cancer, 18 (1), e96-e103
DOI 10.1016/j.clcc.2018.10.001, PubMed 30415990

Smeby J, Sveen A, Merok MA, Danielsen SA, Eilertsen IA, Guren MG, Dienstmann R, Nesbakken A, Lothe RA (2018)
CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer
Ann Oncol, 29 (5), 1227-1234
DOI 10.1093/annonc/mdy085, PubMed 29518181

Steinberg MT, Olsen JA, Eriksen M, Neset A, Norseng PA, Kramer-Johansen J, Hardig BM, Wik L (2018)
Haemodynamic outcomes during piston-based mechanical CPR with or without active decompression in a porcine model of cardiac arrest
Scand J Trauma Resusc Emerg Med, 26 (1), 31
DOI 10.1186/s13049-018-0496-z, PubMed 29690910

Thomsen M, Skovlund E, Sorbye H, Bolstad N, Nustad KJ, Glimelius B, Pfeiffer P, Kure EH, Johansen JS, Tveit KM, Christoffersen T, Guren TK (2018)
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
Br J Cancer, 118 (12), 1609-1616
DOI 10.1038/s41416-018-0115-9, PubMed 29872151

Vermeer NCA, Claassen YHM, Derks MGM, Iversen LH, van Eycken E, Guren MG, Mroczkowski P, Martling A, Johansson R, Vandendael T, Wibe A, Moller B, Lippert H, Portielje JEA, Liefers GJ, Peeters KCMJ, van de Velde CJH, Bastiaannet E (2018)
Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison
Oncologist, 23 (8), 982-990
DOI 10.1634/theoncologist.2017-0551, PubMed 29567826

Publications 2017

Astrup GL, Hofsø K, Bjordal K, Guren MG, Vistad I, Cooper B, Miaskowski C, Rustøen T (2017)
Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence
Acta Oncol, 56 (3), 462-470
DOI 10.1080/0284186X.2016.1273546, PubMed 28077018

Galleberg RB, Knigge U, Tiensuu Janson E, Vestermark LW, Haugvik SP, Ladekarl M, Langer SW, Grønbæk H, Österlund P, Hjortland GO, Assmus J, Tang L, Perren A, Sorbye H (2017)
Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas
Eur J Surg Oncol, 43 (9), 1682-1689
DOI 10.1016/j.ejso.2017.04.010, PubMed 28522174

Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, Österlund P, Sigurdsson F, Lothe IMB, Dalsgaard AM, Skovlund E, Christoffersen T, Tveit KM (2017)
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
Br J Cancer, 116 (10), 1271-1278
DOI 10.1038/bjc.2017.93, PubMed 28399112

Labori KJ, Guren MG, Brudvik KW, Røsok BI, Waage A, Nesbakken A, Larsen S, Dueland S, Edwin B, Bjørnbeth BA (2017)
Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival
Colorectal Dis, 19 (8), 731-738
DOI 10.1111/codi.13622, PubMed 28181384

Rusten E, Rekstad BL, Undseth C, Al-Haidari G, Hanekamp B, Hernes E, Hellebust TP, Malinen E, Guren MG (2017)
Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography
Radiat Oncol, 12 (1), 147
DOI 10.1186/s13014-017-0883-z, PubMed 28874205

Sternby Eilard M, Hagström H, Mortensen KE, Wilsgaard T, Vagnildhaug OM, Dajani O, Stål P, Rizell M (2017)
Quality of life as a prognostic factor for survival in hepatocellular carcinoma
Liver Int, 38 (5), 885-894
DOI 10.1111/liv.13593, PubMed 28941130

Thomsen M, Guren MG, Skovlund E, Glimelius B, Hjermstad MJ, Johansen JS, Kure E, Sorbye H, Pfeiffer P, Christoffersen T, Guren TK, Tveit KM (2017)
Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status
Eur J Cancer, 81, 26-35
DOI 10.1016/j.ejca.2017.04.026, PubMed 28595137

Åsli LM, Johannesen TB, Myklebust TÅ, Møller B, Eriksen MT, Guren MG (2017)
Preoperative chemoradiotherapy for rectal cancer and impact on outcomes - A population-based study
Radiother Oncol, 123 (3), 446-453
DOI 10.1016/j.radonc.2017.04.012, PubMed 28483302

Publications 2016

Cameron MG, Kersten C, Vistad I, van Helvoirt R, Weyde K, Undseth C, Mjaaland I, Skovlund E, Fosså SD, Guren MG (2016)
Palliative pelvic radiotherapy for symptomatic rectal cancer - a prospective multicenter study
Acta Oncol, 55 (12), 1400-1407
DOI 10.1080/0284186X.2016.1191666, PubMed 27332723

Glimelius B, Myklebust TÅ, Lundqvist K, Wibe A, Guren MG (2016)
Two countries - Two treatment strategies for rectal cancer
Radiother Oncol, 121 (3), 357-363
DOI 10.1016/j.radonc.2016.11.010, PubMed 27887734

Røhrl K, Guren MG, Miaskowski C, Cooper BA, Diep LM, Rustøen T (2016)
No Differences in Symptom Burden Between Colorectal Cancer Patients Receiving Curative Versus Palliative Chemotherapy
J Pain Symptom Manage, 52 (4), 539-547
DOI 10.1016/j.jpainsymman.2016.04.008, PubMed 27470003

Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P, Johansen JS, Kure EH, Ikdahl T, Tveit KM, Christoffersen T, Guren TK (2016)
Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
Oncotarget, 7 (46), 75013-75022
DOI 10.18632/oncotarget.12601, PubMed 27738330

Publications 2015

Cameron MG, Kersten C, Vistad I, van Helvoirt R, Weyde K, Undseth C, Mjaaland I, Skovlund E, Fosså SD, Guren MG (2015)
Palliative pelvic radiotherapy for symptomatic incurable prostate cancer – A prospective multicenter study
Radiother Oncol, 115 (3), 314-20
DOI 10.1016/j.radonc.2015.05.021, PubMed 26091575

Gupta S, Argilés G, Munster PN, Hollebecque A, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Piha-Paul SA (2015)
A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies
Clin Cancer Res, 21 (23), 5235-44
DOI 10.1158/1078-0432.CCR-15-0180, PubMed 26187616

Guren MG, Kørner H, Pfeffer F, Myklebust TÅ, Eriksen MT, Edna TH, Larsen SG, Knudsen KO, Nesbakken A, Wasmuth HH, Vonen B, Hofsli E, Færden AE, Brændengen M, Dahl O, Steigen SE, Johansen MJ, Lindsetmo RO, Drolsum A, Tollåli G, Dørum LM, Møller B, Wibe A (2015)
Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010
Acta Oncol, 54 (10), 1714-22
DOI 10.3109/0284186X.2015.1034876, PubMed 25924970

Labori KJ, Schulz A, Drolsum A, Guren MG, Kløw NE, Bjørnbeth BA (2015)
Radiofrequency ablation of unresectable colorectal liver metastases: trends in management and outcome during a decade at a single center
Acta Radiol Open, 4 (7), 2058460115580877
DOI 10.1177/2058460115580877, PubMed 26346740

Leon O, Guren MG, Radu C, Gunnlaugsson A, Johnsson A (2015)
Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer
Eur J Cancer, 51 (18), 2740-6
DOI 10.1016/j.ejca.2015.08.029, PubMed 26597443

Norum J, Traasdahl ER, Totth A, Nieder C, Olsen JA (2015)
Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature
Glob J Health Sci, 8 (4), 1-9
DOI 10.5539/gjhs.v8n4p1, PubMed 26573043

Piha-Paul SA, Munster PN, Hollebecque A, Argilés G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Gupta S (2015)
Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours
Eur J Cancer, 51 (14), 1865-73
DOI 10.1016/j.ejca.2015.06.115, PubMed 26199039

Walters S, Benitez-Majano S, Muller P, Coleman MP, Allemani C, Butler J, Peake M, Guren MG, Glimelius B, Bergström S, Påhlman L, Rachet B (2015)
Is England closing the international gap in cancer survival?
Br J Cancer, 113 (5), 848-60
DOI 10.1038/bjc.2015.265, PubMed 26241817

Wesseltoft-Rao N, Hjermstad MJ, Ikdahl T, Dajani O, Ulven SM, Iversen PO, Bye A (2015)
Comparing two classifications of cancer cachexia and their association with survival in patients with unresected pancreatic cancer
Nutr Cancer, 67 (3), 472-80
DOI 10.1080/01635581.2015.1004728, PubMed 25710201

Publications 2014

Guren MG, Undseth C, Rekstad BL, Brændengen M, Dueland S, Spindler KL, Glynne-Jones R, Tveit KM (2014)
Reirradiation of locally recurrent rectal cancer: a systematic review
Radiother Oncol, 113 (2), 151-7
DOI 10.1016/j.radonc.2014.11.021, PubMed 25613395

Leon O, Guren M, Hagberg O, Glimelius B, Dahl O, Havsteen H, Naucler G, Svensson C, Tveit KM, Jakobsen A, Pfeiffer P, Wanderås E, Ekman T, Lindh B, Balteskard L, Frykholm G, Johnsson A (2014)
Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines
Radiother Oncol, 113 (3), 352-8
DOI 10.1016/j.radonc.2014.10.002, PubMed 25499203

Skrbo N, Hjortland GO, Kristian A, Holm R, Nord S, Prasmickaite L, Engebraaten O, Mælandsmo GM, Sørlie T, Andersen K (2014)
Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft
PLoS One, 9 (11), e113278
DOI 10.1371/journal.pone.0113278, PubMed 25419568

Publications 2013

Bentzen AG, Balteskard L, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, Guren MG (2013)
Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors
Acta Oncol, 52 (4), 736-44
DOI 10.3109/0284186X.2013.770599, PubMed 23438358

Bentzen AG, Guren MG, Vonen B, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, Balteskard L (2013)
Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort
Radiother Oncol, 108 (1), 55-60
DOI 10.1016/j.radonc.2013.05.037, PubMed 23891095

Cameron MG, Kersten C, Guren MG, Fosså SD, Vistad I (2013)
Palliative pelvic radiotherapy of symptomatic incurable prostate cancer - a systematic review
Radiother Oncol, 110 (1), 55-60
DOI 10.1016/j.radonc.2013.08.008, PubMed 24044801

Cameron MG, Kersten C, Vistad I, Fosså S, Guren MG (2013)
Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review
Acta Oncol, 53 (2), 164-73
DOI 10.3109/0284186X.2013.837582, PubMed 24195692

Sveen A, Nesbakken A, Ågesen TH, Guren MG, Tveit KM, Skotheim RI, Lothe RA (2013)
Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
Clin Cancer Res, 19 (24), 6669-77
DOI 10.1158/1078-0432.CCR-13-1769, PubMed 24166914

Publications 2012

Amdal CD, Jacobsen AB, Guren MG, Bjordal K (2012)
Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review
Acta Oncol, 52 (4), 679-90
DOI 10.3109/0284186X.2012.731521, PubMed 23190360

Bentzen AG, Guren MG, Wanderås EH, Frykholm G, Tveit KM, Wilsgaard T, Dahl O, Balteskard L (2012)
Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort
Int J Radiat Oncol Biol Phys, 83 (2), e173-80
DOI 10.1016/j.ijrobp.2011.12.062, PubMed 22436791

Radu C, Norrlid O, Brændengen M, Hansson K, Isacsson U, Glimelius B (2012)
Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients
Acta Oncol, 52 (3), 528-37
DOI 10.3109/0284186X.2012.737022, PubMed 23113591

Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U (2012)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study
Ann Oncol, 24 (1), 152-60
DOI 10.1093/annonc/mds276, PubMed 22967994

Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T (2012)
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
J Clin Oncol, 30 (15), 1755-62
DOI 10.1200/JCO.2011.38.0915, PubMed 22473155

Tveteraas IH, Müller KM, Aasrum M, Ødegård J, Dajani O, Guren T, Sandnes D, Christoffersen T (2012)
Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells
J Exp Clin Cancer Res, 31, 72
DOI 10.1186/1756-9966-31-72, PubMed 22967907

Publications 2011

Brændengen M, Hansson K, Radu C, Siegbahn A, Jacobsson H, Glimelius B (2011)
Delineation of gross tumor volume (GTV) for radiation treatment planning of locally advanced rectal cancer using information from MRI or FDG-PET/CT: a prospective study
Int J Radiat Oncol Biol Phys, 81 (4), e439-45
DOI 10.1016/j.ijrobp.2011.03.031, PubMed 21641122

Brændengen M, Tveit KM, Hjermstad MJ, Johansson H, Berglund Å, Brandberg Y, Glimelius B (2011)
Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study
Eur J Cancer, 48 (6), 813-9
DOI 10.1016/j.ejca.2011.06.035, PubMed 21782418

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E (2011)
Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
BMC Cancer, 11, 455
DOI 10.1186/1471-2407-11-455, PubMed 22014070

Müller KM, Tveteraas IH, Aasrum M, Ødegård J, Dawood M, Dajani O, Christoffersen T, Sandnes DL (2011)
Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells
BMC Cancer, 11, 421
DOI 10.1186/1471-2407-11-421, PubMed 21961726

Publications 2010

Brændengen M, Tveit KM, Bruheim K, Cvancarova M, Berglund Å, Glimelius B (2010)
Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study
Int J Radiat Oncol Biol Phys, 81 (4), 1017-24
DOI 10.1016/j.ijrobp.2010.07.007, PubMed 20932687

Marienhagen K, Helland A, Nordberg T, Guren MG, Hofsli E (2010)
[How do Norwegian oncologists perceive their working conditions?]
Tidsskr Nor Laegeforen, 130 (5), 487-9
DOI 10.4045/tidsskr.08.0305, PubMed 20224615

Robberstad B, Olsen JA (2010)
The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study
Cost Eff Resour Alloc, 8, 5
DOI 10.1186/1478-7547-8-5, PubMed 20398367

Publications 2009

Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O (2009)
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
Mol Oncol, 3 (5-6), 469-82
DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161

Bruheim K, Guren MG, Dahl AA, Skovlund E, Balteskard L, Carlsen E, Fosså SD, Tveit KM (2009)
Sexual function in males after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 76 (4), 1012-7
DOI 10.1016/j.ijrobp.2009.03.075, PubMed 19880263

Bruheim K, Guren MG, Skovlund E, Hjermstad MJ, Dahl O, Frykholm G, Carlsen E, Tveit KM (2009)
Late side effects and quality of life after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 76 (4), 1005-11
DOI 10.1016/j.ijrobp.2009.03.010, PubMed 19540058

Publications 2008

Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Påhlman L, Wiig JN, Byström P, Bujko K, Glimelius B (2008)
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer
J Clin Oncol, 26 (22), 3687-94
DOI 10.1200/JCO.2007.15.3858, PubMed 18669453

Bruheim K, Svartberg J, Carlsen E, Dueland S, Haug E, Skovlund E, Tveit KM, Guren MG (2008)
Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH
Int J Radiat Oncol Biol Phys, 70 (3), 722-7
DOI 10.1016/j.ijrobp.2007.10.043, PubMed 18262088

Sørbye H, Braendengen M, Balteskard L (2008)
[Palliative chemotherapy and radiotherapy for metastatic colorectal cancer]
Tidsskr Nor Laegeforen, 128 (2), 194-7
PubMed 18202732

Publications 2007

Meisdalen K, Dajani OF, Christoffersen T, Sandnes D (2007)
Prostaglandins enhance epidermal growth factor-induced DNA synthesis in hepatocytes by stimulation of E prostanoid 3 and F prostanoid receptors
J Pharmacol Exp Ther, 322 (3), 1044-50
DOI 10.1124/jpet.107.121277, PubMed 17567965

Publications 2006

Guren MG, Tobiassen LB, Trygg KU, Drevon CA, Dueland S (2006)
Dietary intake and nutritional indicators are transiently compromised during radiotherapy for rectal cancer
Eur J Clin Nutr, 60 (1), 113-9
DOI 10.1038/sj.ejcn.1602274, PubMed 16205744

Publications 2005

Guren MG, Eriksen MT, Wiig JN, Carlsen E, Nesbakken A, Sigurdsson HK, Wibe A, Tveit KM, Norwegian Rectal Cancer Group (2005)
Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer
Eur J Surg Oncol, 31 (7), 735-42
DOI 10.1016/j.ejso.2005.05.004, PubMed 16180267

Guren TK, Christoffersen T, Thoresen GH, Wisløff F, Dajani O, Tveit KM (2005)
[Antineoplastic agents targeting tyrosine kinases]
Tidsskr Nor Laegeforen, 125 (22), 3115-9
PubMed 16299568

Sauer T, Guren MG, Noren T, Dueland S (2005)
Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?
Histopathology, 47 (6), 560-4
DOI 10.1111/j.1365-2559.2005.02252.x, PubMed 16324192

Solberg TK, Olsen JA, Ingebrigtsen T, Hofoss D, Nygaard OP (2005)
Health-related quality of life assessment by the EuroQol-5D can provide cost-utility data in the field of low-back surgery
Eur Spine J, 14 (10), 1000-7
DOI 10.1007/s00586-005-0898-2, PubMed 15843969

Publications 2004

Guren MG, Schneede J, Tveit KM, Ueland PM, Nexø E, Dueland S (2004)
Biochemical signs of impaired cobalamin status during and after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 60 (3), 807-13
DOI 10.1016/j.ijrobp.2004.04.018, PubMed 15465197

Sørbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, Øgreid D, Dahl O (2004)
Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer
J Clin Oncol, 22 (1), 31-8
DOI 10.1200/JCO.2004.05.188, PubMed 14701765

Uzdensky AB, Juzeniene A, Kolpakova E, Hjortland GO, Juzenas P, Moan J (2004)
Photosensitization with protoporphyrin IX inhibits attachment of cancer cells to a substratum
Biochem Biophys Res Commun, 322 (2), 452-7
DOI 10.1016/j.bbrc.2004.07.132, PubMed 15325251

Publications 2003

Dolan P, Olsen JA, Menzel P, Richardson J (2003)
An inquiry into the different perspectives that can be used when eliciting preferences in health
Health Econ, 12 (7), 545-51
DOI 10.1002/hec.760, PubMed 12825207

Dueland S, Guren MG, Olsen DR, Poulsen JP, Magne Tveit K (2003)
Radiation therapy induced changes in male sex hormone levels in rectal cancer patients
Radiother Oncol, 68 (3), 249-53
DOI 10.1016/S0167-8140(03)00120-8, PubMed 13129632

Wiig JN, Waehre H, Larsen SG, Braendengen M, Giercksky KE (2003)
Radical prostatectomy for locally advanced primary or recurrent rectal cancer
Eur J Surg Oncol, 29 (5), 455-8
DOI 10.1016/S0748-7983(03)00030-1, PubMed 12798751

Publications 2002

Engebraaten O, Hjortland GO, Juell S, Hirschberg H, Fodstad O (2002)
Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals
Int J Cancer, 97 (6), 846-52
DOI 10.1002/ijc.10137, PubMed 11857366

Friesen SA, Hjortland GO, Madsen SJ, Hirschberg H, Engebraten O, Nesland JM, Peng Q (2002)
5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review)
Int J Oncol, 21 (3), 577-82
PubMed 12168102

Melien O, Nilssen LS, Dajani OF, Sand KL, Iversen JG, Sandnes DL, Christoffersen T (2002)
Ca2+-mediated activation of ERK in hepatocytes by norepinephrine and prostaglandin F2 alpha: role of calmodulin and Src kinases
BMC Cell Biol, 3, 5
DOI 10.1186/1471-2121-3-5, PubMed 11914123

Wiig JN, Poulsen JP, Larsen S, Braendengen M, Waehre H, Giercksky KE (2002)
Total pelvic exenteration with preoperative irradiation for advanced primary and recurrent rectal cancer
Eur J Surg, 168 (1), 42-8
DOI 10.1080/110241502317307562, PubMed 12022371

Publications 2001

Uzdensky AB, Ma LW, Iani V, Hjortland GO, Steen HB, Moan J (2001)
Intracellular localisation of hypericin in human glioblastoma and carcinoma cell lines
Lasers Med Sci, 16 (4), 276-83
DOI 10.1007/PL00011364, PubMed 11702633

Publications 1999

Engebraaten O, Hjortland GO, Hirschberg H, Fodstad O (1999)
Growth of precultured human glioma specimens in nude rat brain
J Neurosurg, 90 (1), 125-32
DOI 10.3171/jns.1999.90.1.0125, PubMed 10413165

Sandnes D, Dajani O, Bjørneby A, Christoffersen T (1999)
The relationship between activation of phosphoinositide-specific phospholipase C and growth stimulation by Ca2+-mobilizing hormones in hepatocytes
Pharmacol Toxicol, 84 (5), 234-40
DOI 10.1111/j.1600-0773.1999.tb01488.x, PubMed 10361980

Publications 1996

Braendengen M, Winderen M, Fosså SD (1996)
Clinical significance of routine pre-cystectomy bone scans in patients with muscle-invasive bladder cancer
Br J Urol, 77 (1), 36-40
DOI 10.1046/j.1464-410X.1996.08467.x, PubMed 8653315

Guren TK, Thoresen GH, Dajani OF, Taraldsrud E, Moberg ER, Christoffersen T (1996)
Epidermal growth factor behaves as a partial agonist in hepatocytes: effects on DNA synthesis in primary culture and competition with transforming growth factor alpha
Growth Factors, 13 (3-4), 171-9
DOI 10.3109/08977199609003219, PubMed 8919025

Publications 1995

FRECH W, BAXTER DC, DYVIK G, DYBDAHL B (1995)
ON THE DETERMINATION OF TOTAL MERCURY IN NATURAL GASES USING THE AMALGAMATION TECHNIQUE AND COLD VAPOR ATOMIC-ABSORPTION SPECTROMETRY
J. Anal. At. Spectrom., 10 (10), 769-775

Refsnes M, Dajani OF, Sandnes D, Thoresen GH, Røttingen JA, Iversen JG, Christoffersen T (1995)
On the mechanisms of the growth-promoting effect of prostaglandins in hepatocytes: the relationship between stimulation of DNA synthesis and signaling mediated by adenylyl cyclase and phosphoinositide-specific phospholipase C
J Cell Physiol, 164 (3), 465-73
DOI 10.1002/jcp.1041640304, PubMed 7650056

Thoresen GH, Refsnes M, Dajani OF, Johansen EJ, Christoffersen T (1995)
Dexamethasone inversely regulates DNA synthesis and phosphoenolpyruvate carboxykinase mRNA levels in cultured rat hepatocytes: interactions with insulin, glucagon, and transforming growth factor beta 1
Pharmacol Toxicol, 76 (3), 163-70
DOI 10.1111/j.1600-0773.1995.tb00124.x, PubMed 7617540

Publications 1994

Refsnes M, Thoresen GH, Dajani OF, Christoffersen T (1994)
Stimulation of hepatocyte DNA synthesis by prostaglandin E2 and prostaglandin F2 alpha: additivity with the effect of norepinephrine, and synergism with epidermal growth factor
J Cell Physiol, 159 (1), 35-40
DOI 10.1002/jcp.1041590106, PubMed 8138589

Publications 1992

Refsnes M, Thoresen GH, Sandnes D, Dajani OF, Dajani L, Christoffersen T (1992)
Stimulatory and inhibitory effects of catecholamines on DNA synthesis in primary rat hepatocyte cultures: role of alpha 1- and beta-adrenergic mechanisms
J Cell Physiol, 151 (1), 164-71
DOI 10.1002/jcp.1041510121, PubMed 1313818

Publications 1990

Thoresen GH, Sand TE, Refsnes M, Dajani OF, Guren TK, Gladhaug IP, Killi A, Christoffersen T (1990)
Dual effects of glucagon and cyclic AMP on DNA synthesis in cultured rat hepatocytes: stimulatory regulation in early G1 and inhibition shortly before the S phase entry
J Cell Physiol, 144 (3), 523-30
DOI 10.1002/jcp.1041440321, PubMed 2167904